In an industry where supply chains are closely monitored, patient data is king, and complex medications require high-touch services by distribution partners, biologics and pharmaceutical manufacturers have turned to specialty... Read More
Life Sciences | Manufacturers | Pharmacy Law | Private Equity Investing in Specialty Pharmacy & Pharmaceutical Companies

The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
Blogs & Articles | Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Section 340B In-House and Contract Pharmacies

In this White Paper, the National Association of Specialty Pharmacy (NASP) and Frier Levitt explore the disparate impact that certain Pharmacy Benefit Managers (PBMs) "Direct and Indirect Remuneration" fees (commonly known as "DIR Fees") have on... Read More
Defending Pharmacies in PBM Audits | Pharmacy Law | Webinars